A5023234511- Colorectal Cancer Treatments and Studies
- Neuroendocrine Tumor Research Advances
- Lung Cancer Research Studies
- Genetic factors in colorectal cancer
- Pancreatic and Hepatic Oncology Research
- Neuroblastoma Research and Treatments
- Gastric Cancer Management and Outcomes
- Cancer Treatment and Pharmacology
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Surgical Treatments
- Helicobacter pylori-related gastroenterology studies
- Lung Cancer Treatments and Mutations
- Gestational Trophoblastic Disease Studies
- Colorectal and Anal Carcinomas
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Radiomics and Machine Learning in Medical Imaging
- Management of metastatic bone disease
- Gastroesophageal reflux and treatments
- Metastasis and carcinoma case studies
- Chemotherapy-induced cardiotoxicity and mitigation
- Protease and Inhibitor Mechanisms
- Health Systems, Economic Evaluations, Quality of Life
- Frailty in Older Adults
Haukeland University Hospital
2015-2024
University of Bergen
2015-2024
Oslo University Hospital
2012-2014
Hôpital Ambroise-Paré
2008-2014
OsloMet – Oslo Metropolitan University
2014
Norwegian University of Life Sciences
2014
University of Oslo
2014
Cancer Registry of Norway
2014
Telemark Hospital
2014
European Organisation for Research and Treatment of Cancer
2014
Adrenocortical carcinoma is a rare cancer that has poor response to cytotoxic treatment.We randomly assigned 304 patients with advanced adrenocortical receive mitotane plus either combination of etoposide (100 mg per square meter body-surface area on days 2 4), doxorubicin (40 day 1), and cisplatin 3 4) (EDP) every 4 weeks or streptozocin (streptozotocin) (1 g 1 5 in cycle 1; subsequent cycles) weeks. Patients disease progression received the alternative regimen as second-line therapy. The...
are not a homogenous entity and can be further subclassified into biologically relevant subgroups.A separation based on the proliferative index (Ki-67 >55%) was shown to have clinical implications regarding response chemotherapy prognosis: NEC with Ki-67 >55% responded better platinum-based and, nevertheless, had 4 months' shorter median survival than G3 NEN in lower range (20-55%) [1] .More recent publications show that morphological differentiation able separate prognostic groups among...
The NORDIC-VII multicenter phase III trial investigated the efficacy of cetuximab when added to bolus fluorouracil/folinic acid and oxaliplatin (Nordic FLOX), administered continuously or intermittently, in previously untreated metastatic colorectal cancer (mCRC). influence KRAS mutation status on treatment outcome was also investigated.Patients were randomly assigned receive either standard Nordic FLOX (arm A), B), combined with intermittent C). Primary end point progression-free survival...
The primary aim of our study was to evaluate the safety and potential toxicity gemcitabine combined with microbubbles under sonication in inoperable pancreatic cancer patients. secondary a novel image-guided microbubble-based therapy, based on commercially available technology, towards improving chemotherapeutic efficacy, preserving patient performance status, prolonging survival. Ten patients were enrolled treated this Phase I clinical trial. Gemcitabine infused intravenously over 30 min....
Abstract BACKGROUND: Patients with metastatic poorly differentiated endocrine carcinoma (PDEC) usually have a short survival. The chemotherapy combination of cisplatin and etoposide is frequently used as first‐line palliative chemotherapy. There are, however, no published studies concerning second‐line treatment the disease. Temozolomide has shown clinical effect in well‐differentiated carcinomas. This study was performed to evaluate temozolomide PDEC patients who had progressed on...
The European Neuroendocrine Tumor Society (ENETS) proposed standard of care guidelines for pathology in 2009. Since then, profound changes the classification have been made, dividing neuroendocrine neoplasia (NEN) into well-differentiated tumors (NET) and poorly differentiated carcinomas (NEC) 2010 WHO classification. 7th edition TNM (2009) included NEN first time, widely adapting ENETS proposals but with some differences NEC NET pancreas appendix. Therapy gastroenteropancreatic were updated...
BACKGROUND Extrapulmonary neuroendocrine carcinomas (NECs) are poorly studied and managed similar to lung NECs, which may not account for differences between the 2 groups of tumors as well heterogeneity within extrapulmonary NEC. METHODS Data from Surveillance, Epidemiology, End Results program 1973 2012 were used estimate relative percentages NECs subgroups epidemiological patterns at these sites, median 5‐year overall survival rates. RESULTS Of 162,983 NEC cases, 14,732 extrapulmonary;...
This ENETS guidance paper, developed by a multidisciplinary working group, provides up-to-date and practical advice on the diagnosis management of digestive neuroendocrine carcinoma, based recent developments study results. These recommendations aim to pave road for more standardized care our patients resulting in improved outcomes. Prognosis is generally poor NEC, most are advanced at median survival metastatic disease 11-12 months. Surgery can be benefit localized after extensive...
Systemic therapies established in the management of patients with neuroendocrine tumors (NETs) include somatostatin analogs and interferon-α, also referred to as biotherapy. Recent randomized controlled studies have extended knowledge on frequency side effects associated More recently, novel targeted drugs, such mammalian target rapamycin inhibitor everolimus multiple tyrosine kinase sunitinib, been introduced NETs. Although drugs are generally well tolerated, most adverse events being mild...
Peptide receptor radionuclide therapy (PRRT) is an established treatment of metastatic neuroendocrine tumors grade 1-2 (G1-G2). However, its possible benefit in high-grade gastroenteropancreatic (GEP) neoplasms (NEN G3) largely unknown. We therefore aimed to assess the benefits and side effects PRRT patients with GEP NEN G3. performed a retrospective cohort study at 12 centers efficacy toxicity Outcomes were response rate, disease control progression-free survival (PFS), overall (OS)...
Systemic chemotherapy is indicated in progressive or bulky advanced pancreatic neuroendocrine tumors (NETs) and grade 3 (G3) neoplasms (NENs) as per ENETS guidelines. Chemotherapy may be considered NETs of other sites (lung, thymus, stomach, colon, rectum) under certain conditions (e.g., when Ki-67 at a high level [upper G2 range], rapidly disease and/or after failure therapies, if somatostatin receptor imaging negative). An Consensus Conference was held Antibes (2015) to elaborate...
RAS and BRAF mutations impact treatment prognosis of metastatic colorectal cancer patients (mCRC), but the knowledge is based on trial usually not representative for general population. Patient characteristics, efficacy according to KRAS, MSI status were analyzed in a prospectively collected unselected population-based cohort 798 non-resectable mCRC patients. The contained many with poor performance (39% PS 2-4) elderly (37% age>75), groups included clinical trials. Patients without...
Pancreatic cancer is the fourth leading cause of cancer-related death. While surgical resection remains foundation for potentially curative treatment, survival benefit achieved with adjuvant oncological treatment. Thus, completion multimodality treatment (surgical and (neo)adjuvant chemotherapy) to all patients early micrometastatic disease ideal goal. NorPACT–1 aims test hypothesis that overall mortality at one year after allocation can be reduced neoadjuvant chemotherapy in surgically...
High-grade gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are classified according to morphology as well-differentiated tumours (NETs) G3 or poorly differentiated carcinomas (NECs). Little data exist concerning which morphological criteria this subdivision should be based on. Uncertainty exists if the NEC group further subdivided proliferation rate. Clinical on NET and with a lower Ki-67 range limited. A total of 213 patients high-grade GEP-NEN (Ki-67 >20%) were included...
High-grade (HG) gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) are rare but have a very poor prognosis and represent severely understudied class of tumours. Molecular data for HG GEP-NEN limited, treatment strategies the carcinoma subgroup (HG GEP-NEC) extrapolated from small-cell lung cancer (SCLC). After pathological re-evaluation, we analysed DNA tumours matched blood samples 181 patients; 152 carcinomas (NEC) 29 (NET G3). Based on sequencing 360 cancer-related genes,...
Trial accrual patterns were examined to determine whether metastatic colorectal cancer (mCRC) patients enrolled in trials are representative of a general population concerning patient characteristics and survival.A total 760 mCRC referred for their first oncological consideration at 3 hospitals Scandinavia covering defined populations registered consecutively during 2003 2006. Clinical trial enrollment, characteristics, treatment recorded prospectively, the follow-up was complete.Palliative...
Irinotecan and 5-fluorouracil (5-FU) are used to treat metastatic colorectal cancer. Irinotecan's active metabolite is inactivated by UDP-glucuronosyltransferase 1A1 (UGT1A1), which deficient in Gilbert's syndrome. metabolites transported P-glycoprotein, encoded ABCB1. 5-FU targets folate metabolism through inhibition of thymidylate synthase (TYMS). Methylenetetrahydrofolate reductase (MTHFR) generates necessary for haematopoiesis. We retrospectively genotyped 140 Swedish Norwegian...
In EORTC study 40983, perioperative FOLFOX increased progression-free survival (PFS) compared with surgery alone for patients initially 1 to 4 resectable liver metastases from colorectal cancer (CRC). We conducted an exploratory retrospective analysis identify baseline factors possibly predictive a benefit of on PFS.The was based 237 events 342 eligible patients. Cox proportional hazards regression models significance level 0.1 were used build up univariate and multivariate models.After...